Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
In the trial, there was no statistical difference in estimated hypoglycaemia rates, and no severe hypoglycaemia events were observed for people treated with insulin icodec
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
A centralised kitchen which provides 5,000 breakfast meals per day is to be started at Perumallapuram, Kakinada, Andhra Pradesh
Pre-exposure prevention trial reduced risk of symptomatic Covid-19, with no severe disease or Covid-19-related deaths in the Evusheld group
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Subscribe To Our Newsletter & Stay Updated
